Avista Healthcare Public Acquisition will merge with the regenerative medicine company Organogenesis.
Here are four things to know:
1. Organogenesis will become a wholly owned subsidiary of Avista.
2. Avista Capital Partners' affiliates agreed to invest $92 million in the combined company in conjunction with the transaction.
3. The combined company's anticipated initial enterprise value is approximately $673 million.
4. Organogenesis offers bioactive and acellular biomaterials products in advanced wound care, sports medicine and surgical biologics, including orthopedics and spine.